2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

5421 Efficacy, survival, and safety of first-line BTKi plus R-CHOP versus Pola-R-CHP in diffuse large B-cell lymphoma: A real-world propensity score-matched study

Li Zhou, N/A, Tao You, MD2, Depei Wu Sr, MD3, Haiwen Huang, PhD4
1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
2 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
3 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
4 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Background
R-CHOP remains the standard first-line treatment for diffuse large B-cell lymphoma (DLBCL); however, outcomes remain suboptimal in patients with intermediate- to high-risk disease, many of whom ultimately develop relapsed or refractory disease. Bruton tyrosine kinase inhibitor (BTKi) plus R-CHOP and polatuzumab vedotin plus R-CHP (Pola-R-CHP) have been evaluated as first-line treatment strategies for DLBCL. This study aimed to compare the efficacy, survival outcomes, and safety of these two regimens and to identify prognostic factors associated with clinical outcomes.

Methods
We retrospectively enrolled treatment-naïve patients with DLBCL who received first-line BTKi plus R-CHOP or Pola-R-CHP. The data cutoff was June 10, 2026. Patients were matched 1:1 using nearest-neighbor propensity score matching (PSM) based on age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, lactate dehydrogenase (LDH) level, Ann Arbor stage, International Prognostic Index (IPI), bulky disease, B symptoms, extranodal involvement, and Hans classification. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included overall response rate (ORR), event-free survival (EFS), time to next treatment (TTNT), and hematologic adverse events. Survival outcomes were analyzed using the Kaplan–Meier method, the log-rank test, and Cox proportional hazards models.

Results
A total of 69 patients treated with BTKi plus R-CHOP and 61 treated with Pola-R-CHP were included. After 1:1 propensity score matching, 43 matched pairs were identified. Baseline characteristics were generally well balanced after matching, although residual imbalance remained in lactate dehydrogenase (LDH) level and bulky disease. Among evaluable patients, the complete response (CR) rates were 82.9% and 65.1% (P=0.123), and the overall response rates (ORRs) were 88.6% and 83.7% (P=0.746) in the BTKi plus R-CHOP and Pola-R-CHP groups, respectively. The median progression-free survival (PFS) was not reached in either group. The 24-month PFS rates were 73.1% and 75.7%, respectively, with no significant difference between the two regimens (HR, 1.00; 95% CI, 0.39–2.60; P=0.996). Event-free survival (EFS) and time to next treatment (TTNT) were also comparable between the groups. Only one death occurred after matching, and the overall survival (OS) data remained immature. On multivariable Cox regression analysis, an International Prognostic Index (IPI) score of 3–5 (HR, 2.61; 95% CI, 1.10–6.19; P=0.029) and bulky disease (HR, 4.47; 95% CI, 1.84–10.84; P<0.001) were independently associated with inferior PFS, whereas treatment regimen was not significantly associated with PFS. The incidence of hematologic adverse events was comparable between the two groups. Next-generation sequencing (NGS) analysis identified no significant genomic biomarkers after adjustment for multiple testing.

Conclusions
Both regimens achieved high response rates, with no significant differences observed in PFS, EFS, TTNT, or hematologic adverse events. However, these findings do not establish therapeutic equivalence between the two treatment strategies. An International Prognostic Index (IPI) score of 3–5 and bulky disease were identified as independent adverse prognostic factors for PFS. Given the limited number of OS events, these findings should be considered exploratory and require validation in larger prospective studies with longer follow-up.

Haiwen Huang, PhD: No relevant conflicts of interest to declare.